RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
RenovoRx, Inc.NASDAQ: RNXT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $254K fell 33.3% year over year, ahead of the -85.9% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +187.1% a year.
Context
- Accounts payables amounted to 19.0% of revenue in FY2025, down 39.2 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -85.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 213K USD
- Year-over-year change
- +752.0%
- 4-year CAGR
- -12.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 213K | +752.0% |
| FY2024 | 2024-12-31 | 25K | -7.4% |
| FY2023 | 2023-12-31 | 27K | +200.0% |
| FY2022 | 2022-12-31 | 9K | -97.5% |
| FY2021 | 2021-12-31 | 363K | — |
Accounts Payables vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 accounts payables of $86K is the 5th largest of the 6 companies compared; the peer median is $1.1M.
- Its year-over-year change of -85.9% is the 4th highest of 5, against a peer median of +91.1%.
- Accounts payables amounts to 5.8% of revenue for RNXT, versus a peer median of 11.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.91M | +242.7% | -55.7% | — | |
| LTM Dec 2025 | $3.13M | -60.6% | — | 11.8% | |
| LTM Mar 2026 | $1.1M | +34055.9% | +35.0% | — | |
| LTM Mar 2026 | $884.66K | -352.6% | — | — | |
| LTM Mar 2026 | $86K | -85.9% | +187.1% | 5.8% | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding RNXT) | $1.1M | +91.1% | -10.4% | 11.8% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Depreciation & Amortization | 9K | 6K | 0 | 0 | 2K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 147K | 644K | 1.08M | 1.17M | 1.27M |
| Change in Working Capital | (265K) | 428K | 605K | 280K | (247K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (96K) |
| Inventory | 0 | 0 | 0 | 0 | (189K) |
| Accounts Payables | 363K | 9K | 27K | 25K | 213K |
| Other Working Capital | (628K) | 419K | 578K | 255K | (175K) |
| Other Non-Cash Items | 517K | 0 | (1.71M) | (1.77M) | (827K) |
| Operating Cash Flow | (5.92M) | (8.81M) | (10.26M) | (9.13M) | (10.97M) |
| Capital Expenditures | (15K) | 0 | 0 | (12K) | (2K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (8M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 5.97M | 2.03M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (15K) | (2.03M) | 2.03M | (12K) | (2K) |
| Debt Repayment | 1.98M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 14.56M | 42K | 5M | 15.02M | 12.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.79M | 0 | 8K | 102K | (1.3M) |
| Financing Cash Flow | 19.33M | 42K | 5.01M | 15.12M | 10.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 13.4M | (10.8M) | (3.22M) | 5.98M | (130K) |
| Free Cash Flow | (5.93M) | (8.81M) | (10.26M) | (9.14M) | (10.98M) |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.